Affimed announced that the FDA has granted Fast Track designation to the combination of its innate cell engager AFM24 with atezolizumab for the treatment of patients with advanced and/or metastatic non-small cell lung cancer not harboring any activating EGFR mutations after progression on PD-(L)1 targeted therapy and platinum-based chemotherapy. Data from the AFM24-102 study in this patient population will be presented at the upcoming annual meeting of the American Society of Clinical Oncology on June 1, 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AFMD:
- Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
- Affimed Schedules 2024 Shareholders Meeting
- Affimed Announces Annual General Meeting of Shareholders
- Affimed’s Study Shows New Cancer Treatment Promise
- Affimed to present efficacy results of NSCLC combination therapy